Clinical Trial Update: Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial update describes the safety and tolerability assessment of subretinal OPGx-001 for Leber congenital amaurosis 5–associated inherit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis Type

Drugs mentioned

• OPGx-001

Snippet

Sponsor: Opus Genetics, Inc | Conditions: LCA5 | Phase 1, Phase 2 | Status: RECRUITING